Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

Abstract

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.

Comparison of non-invasive approaches to red marrow dosimetry for radiolabelled monoclonal antibodies

“…Radionuclide therapy does not suffer from this limitation and represents an attractive option. In patients treated with radiolabelled MAbs or bone-seeking tracers (strontium-89, rhenium-186 diphosphonate) the red marrow often is the critical tissue in terms of dose-limiting toxicity [24,25].…”

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

“…Of these 31 studies, 6 reported on bone metastases from breast cancer, [71][72][73][74][75][76] 13 reported on bone metastases from prostate cancer [77][78][79][80][81][82][83][84][85][86][87][88][89] and 12 reported on bone metastases from OSTs. [90][91][92][93][94][95][96][97][98][99][100][101] Of the remaining eight studies that did contribute data to the network meta-analyses, four reported breast cancer 31,[102][103][104] [18 reports 22,31,[102][103][104][105][106][107][108][109][110][111][112][113][11...…”

Strontium-89 (Metastron) in the Treatment of Prostate Cancer Metastatic to Bone

“…As Metastron is a pure ß-emitter, it therefore stands to reason that a considerable amount of the tumour may in fact be underirradiated by the use of a single injection. Arguments for the use of Metastron in multiple therapies, as has been performed by Buchali et al [29] and Tenvall et al [31], may thus be valid. Recogni tion of the factors underlying the radiobiological response to radiation has also been increasing, particularly regard ing radiation at ultra-low dose rates.…”

“…In the Trans Canada study, the median survival was 34 weeks in patients receiving placebo [27], A treatment that will extend quality-assured survival in this population is, therefore, much needed. Buchali et al [29] evaluated 49 patients after treatment with either Metastron, at a dose of 2 mCi monthly for 3 months, or a saline placebo. A statistically significant prolongation of survival was seen in the group receiving Metastron.…”